Lipocomb

Ezetimibe, the active ingredient in Lipocomb, is a cholesterol absorption inhibitor presented as a tablet for oral use. It reduces intestinal cholesterol absorption, helping to lower LDL‑cholesterol in adults with primary hypercholesterolemia or mixed dyslipidemia. The combination also includes rosuvastatin zinc, a potent HMG‑CoA reductase inhibitor that further decreases hepatic cholesterol synthesis and up‑regulates LDL receptors, enhancing overall lipid control.

GNH USA supplies Lipocomb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across all markets.

Lipocomb, a fixed‑dose combination of ezetimibe and rosuvastatin, is used to manage disorders of lipid metabolism. - Hypercholesterolemia: lowers LDL‑cholesterol and total cholesterol levels. - Mixed dyslipidemia: improves LDL, triglycerides and HDL profiles. - Primary prevention of cardiovascular events: reduces risk of myocardial infarction and stroke in high‑risk patients. - Heterozygous familial hypercholesterolemia: provides additional LDL‑cholesterol reduction when statin monotherapy is insufficient.

Lipocomb may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Headache: mild to moderate headache reported in clinical use. - Myalgia: muscle aches without significant CK elevation. - Abdominal discomfort: nausea, dyspepsia or flatulence. - Elevated liver enzymes: transient increase in ALT/AST. - Diarrhea: loose stools. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Myopathy/Rhabdomyolysis: severe muscle breakdown, especially with high‑dose statins. - Severe hepatic injury: marked elevation of transaminases or jaundice. - Allergic reactions: rash, pruritus or angioedema.

Before prescribing Lipocomb, clinicians should consider several precautionary measures to ensure patient safety. - Liver function monitoring: assess baseline ALT/AST and repeat periodically. - Renal impairment: adjust therapy in severe kidney disease. - Drug interactions: review concomitant medications that affect statin metabolism. - Pregnancy and lactation: avoid use unless benefits outweigh risks. - Muscle disorders: discontinue if signs of myopathy appear. - Store at ambient temperature: keep tablets in original container, protect from moisture and light.

Lipocomb can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase rosuvastatin exposure, risk of myopathy. - Cyclosporine: markedly raises rosuvastatin levels, contraindicated. - Gemfibrozil: enhances statin‑related muscle toxicity. - Antacids containing aluminum/magnesium: may reduce ezetimibe absorption.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR, monitor coagulation. - Niacin: additive effect on liver enzymes. - Other fibrates (excluding gemfibrozil): monitor for muscle symptoms.